BioLife Solutions, Inc. (NASDAQ:BLFS) was upgraded by investment analysts at Janney Montgomery Scott from a “neutral” rating to a “buy” rating in a research note issued to investors on Wednesday, July 5th, Marketbeat reports. The brokerage presently has a $5.00 price objective on the medical equipment provider’s stock, up from their prior price objective of $2.62. Janney Montgomery Scott’s price target would suggest a potential upside of 47.06% from the company’s current price.

Separately, Maxim Group set a $4.00 price target on BioLife Solutions and gave the company a “buy” rating in a research note on Saturday, May 13th.

BioLife Solutions (NASDAQ BLFS) traded up 0.72% during trading on Wednesday, reaching $3.40. 671,795 shares of the company were exchanged. The company’s market capitalization is $44.32 million. BioLife Solutions has a one year low of $1.43 and a one year high of $3.74. The firm’s 50-day moving average is $2.26 and its 200 day moving average is $2.01.

BioLife Solutions (NASDAQ:BLFS) last released its earnings results on Thursday, May 11th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.02. BioLife Solutions had a negative return on equity of 74.36% and a negative net margin of 74.58%. The business had revenue of $2.37 million during the quarter, compared to analysts’ expectations of $2.10 million. On average, analysts anticipate that BioLife Solutions will post ($0.17) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “BioLife Solutions, Inc. (NASDAQ:BLFS) Rating Increased to Buy at Janney Montgomery Scott” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at

About BioLife Solutions

BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.

Receive News & Stock Ratings for BioLife Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions Inc. and related stocks with our FREE daily email newsletter.